When it comes to HIV and gay, the words become synonymous. So… a new study released believes if 20 percent of high-risk men took the pill daily, there would be nearly 63,000 fewer infections.
According to the NY Daily News, the study by experts at Stanford University, published in the Annals of Internal Medicine, looked at the costs involved with prescribing a $26 a day pill to men who have sex with men. Prescribing the pill generally to men who have sex with men in the United States would cost $495 billion over 20 years, but targeting those at highest risk only would bring costs down to $85 billion, said the study.
With researching garnering more support, a clinical trial found that the drug reduced a person’s risk of HIV infection by an average of 44 percent when taken daily. In some people, the drug reduced the risk by 73 percent. In a 2010 trial, Truvada was shown to prevent HIV infections in men who have sex with men (MSM) who took it regularly.
“Promoting PrEP to all men who have sex with men could be prohibitively expensive,” said Jessie Juusola, a PhD candidate in management science and engineering in the Stanford School of Engineering and first author of the study.
Juusola states: Adopting it for men who have sex with men at high risk of acquiring HIV, however, is an investment with good value that does not break the bank.
In order to introduce preventative care, Gilead Sciences Inc., the maker of the pill Truvada, is seeking approval to launch their product on the market for everyone. Normally Truvada is giving to those who have contracted the virus or at high risk.